The biotech sector faces significant financial shifts as major oncology drugs approach patent expiry. A comprehensive analysis details how blockbuster immuno-oncology therapies from the mid-2010s are set to lose exclusivity, risking substantial revenue declines and market disruption. Companies with diversified pipelines are better poised for this transition. Meanwhile, in venture capital, Hatteras Venture Partners secured $200 million for seed- and early-stage biotech investments, signaling resilience amid fundraising challenges.